Statistics for Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.
Total visits
| views | |
|---|---|
| Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose. | 182 |
Total visits per month
| views | |
|---|---|
| December 2024 | 19 |
| January 2025 | 11 |
| February 2025 | 1 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
File Visits
| views | |
|---|---|
| 27_Ribeiro_S_Renal_risk-benefit_determinants_of_recombinant_Clinical_Exp_Pharm_P.pdf(legacy) | 1 |
Top country views
| views | |
|---|---|
| United States | 116 |
| China | 19 |
| India | 10 |
| Ukraine | 7 |
| Brazil | 6 |
| Mongolia | 5 |
| Portugal | 5 |
| Australia | 3 |
| Poland | 3 |
| Argentina | 2 |
| Japan | 2 |
| Austria | 1 |
| Canada | 1 |